ERBB2 and breast carcinoma: Estrogen-, progesterone-receptor-negative human epidermal growth factor 2 (HER2) “negative” breast cancer (also known as triple negative breast cancer (TNBC)) accounts for up to 15–20% of all breast malignancies and has a generally worse prognosis and fewer treatment options relative to more common forms of breast cancer.